GLG News by Cosmetic Dermatologists in Private Practice (US)

The possible ban of over the counter hydroquinone skin bleaching agents may be premature. We have used these agents for 20 years without any significant side effects including ochronosis or paradoxical darkening of the skin. These agents are only modestly effective at best. Most patients still...

The company hopes to apply for European regulatory approval next year, with U.S. market approval and launch to follow. The current price of the device is 15,000 EUR. This device promises to be a remarkable time and money saver for medicine. Approximately 80-95% of lesions excised by dermatologists prove...

Patient satisfaction is high, but long term effects including possible carcinogenesis remain uncertain. Side effects included blistering, and hyperpigmentation in both groups, but no scarring.

In the Plastic Surgery literature wound care via home monitoring is advanced enough to change outcomes.  See Murphy, Bain et al in the Annals of Plastic Surgery June 2005. Home telemonitoring is good for certain problems, that require regular monitoring.  It has been shown to be equivalent...

The recent Epiceram phase 4 data comparing it to Cutivate are positive, and bode well for the product. The concept of barrier repair makes sense in light of the recent findings in regards to the genetic basis of atopic dermatitis. Repairing the barrier with Epiceram will reduce inflammation, and the...

Altabax (retapamulin) will be a competitive topical agent for impetigo because it is a new molecular entity, Bactroban or mupirocin is generic and cannot compete directly, and it is indicated for children as young as 9 months. The market for a nonoral antibiotic is always good, due to lower side ef...

ELEVESS received its CE mark approval in Europe. The product is entering a crowded field with no real differentiating factors other than having lidocaine as an anesthetic. To release this product in the US without a partnership with an established company will be very hard. It will not be easy to compete...

 Altabax is a member of a new class of antibiotics and is a topical treatment for uncomplicated skin and skin structure infections due to susceptible strains of Staphylococcus aureus and Streptococcus pyogenes. It's to be used twice daily use for a five-day period. Altabax’s unique...

Galderma has partnered with Anika to launch a hyaluronic acid product into the marketplace. It will be the first HA filler to be combined with Lidocaine.However, Medicis (with a 3 1/2 year headstart with Restylane) and Allergan's Juvederm will probably still take the lion's share of the filler market....

The phase 2 data for Incyclinide indicate a modest benefit over placebo for the 20 mg dose only, which drops off at 12 weeks. This drug will need a higher dose for efficacy. The premise behind a non antimicrobial antibiotic type medication is valid and intriguing. The next trial results are important...